Diadexus Inc. (GREY:DDXS)

First Quarter 2013 Results

• Total revenues for the first quarter 2013 were $5.6 million, a 12% increase over $4.9 million reported in the first quarter 2012.
• The Company's net loss for the first quarter 2013 narrowed to $1.2 million, or $(0.02) per share, from a net loss of $1.3 million, or $(0.02) per share, in the first quarter 2012.

Brian Ward, Ph.D., diaDexus' President and Chief Executive Officer, said, "diaDexus had a strong first quarter 2013, delivering our 11^th consecutive quarter of year-over-year revenue growth while making investments in our commercial operations and product development to support our long-term growth ambitions. These included the addition of new sales representatives in targeted geographies and increased focus on the development of our new product pipeline. We also continued to drive expanded reimbursement for the PLAC Test, which should help to reduce pricing pressure and have a positive impact on our cardiovascular specialty laboratory partners."

Our blog note from 2/16/2012

Healthcare company with primary focus in heart disease. They possess the only FDA approved blood test, predicting heart disease and a particular type of stroke. Revenues have steadily increased from $300,000 in 2008 to projected $16 million in 2011 and $20 million in 2012. Need to interview to establish break even revenue level.

To be among the first to receive alerts like this, subscribe to our premium service!